Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs, and cardiovascular and cerebrovascular drugs in China and internationally. The company offers drugs in the anesthesia, psychiatry, and neurological categories. It also provides APIs in the areas of central nervous system, anesthetic and sedative, and others. The company was founded in 1978 and is headquartered in Xuzhou, China.

Jiangsu Nhwa Pharmaceutical Co., LTD

江苏恩华药业股份有限公司 is a company focused on the central nervous system drugs segment.

Metric
Company Name	Jiangsu Nhwa Pharmaceutical Co., LTD
Symbol	2.26K
MSH ID	COM:NHWA-GROUP
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	CN
Stage
Employee Count	5.39K
Website	nhwa-group.com
LinkedIn
Founders

Metric
Market Cap	3.09B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	684.09M
Revenue (LTM)
Revenue (NTM)
Gross Profit	483.21M
EBITDA	171.21M
Operating Income	147.12M
Net Income	142.62M
EPS	0.14
Diluted EPS	0.14
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.74
Operating Profit Margin	0.24
EBITDA Margin	0.25
Net Profit Margin	0.22
Return on Equity	0.18
Return on Assets	0.15
Return on Capital Employed	0.18

0022

COM:NHWA-GROUP

江苏恩华药业股份有限公司

Last Close

26.09

25/11 07:04

Market Cap

22.50B

Beta: -

Volume Today

9.50M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	20.84
P/B Ratio	3.45
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.34
EV Multiple	22.25

Metric
Days Sales Outstanding	81.58
Days Payables Outstanding	94.07
Days Inventory Outstanding	196.04
Operating Cycle	277.61
Cash Conversion Cycle	183.54
Asset Turnover	0.70

Metric
Operating Cash Flow	144.50M
Free Cash Flow	93.06M
Cash Flow to Debt	10.58
Operating Cash Flow/Sales	0.23
Free Cash Flow Yield	0.02

Metric
Cash & Equivalents	296.95M
Accounts Receivable	-27.38M
Inventory	86.47M
Goodwill
Debt to Capitalization	0.03
Debt to Assets	0.01
Current Ratio	6.52
Quick Ratio	5.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.11
SG&A to Revenue	0.01